View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 04, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	CLXT
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		32,990,647
Entity Public Float			$ 125,417,099
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Shell Company	false
Entity File Number	001-38161
Entity Tax Identification Number	27-1967997
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock ($(0.0001 par value)
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the registrant’s Annual Meeting of Stockholders to be held in 2020, which definitive proxy statement shall be filed with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 58,610	$ 93,794
Restricted cash	388	381
Trade accounts receivable	1,122
Due from related parties		46
Inventory	2,594
Prepaid expenses and other current assets	808	1,301
Total current assets	63,522	95,522
Non-current restricted cash	1,040	1,113
Land, buildings and equipment	23,212	21,850
Other non-current assets	324	306
Total assets	88,098	118,791
Current liabilities:
Accounts payable	1,077	818
Accrued expenses	2,544	2,007
Accrued compensation and benefits	2,181	1,305
Due to related parties	977	1,905
Current portion of financing lease obligations	356	258
Other current liabilities	61	711
Total current liabilities	7,196	7,004
Financing lease obligations	18,244	18,227
Other non-current liabilities	150	163
Total liabilities	25,590	25,394
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 33,033,689 shares issued and 32,951,329 shares outstanding as of December 31, 2019 and 32,664,429 shares issued and 32,648,893 shares outstanding as of December 31, 2018	3	3
Additional paid-in capital	185,588	176,069
Common stock in treasury, at cost, shares of 82,360 as of December 31, 2019 and 15,536 as of December 31, 2018	(1,043)	(230)
Accumulated deficit	(122,057)	(82,445)
Accumulated other comprehensive income	17
Total stockholders’ equity	62,508	93,397
Total liabilities and stockholders’ equity	$ 88,098	$ 118,791

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	33,033,689	32,664,429
Common stock, shares outstanding	32,951,329	32,648,893
Treasury stock, shares	82,360	15,536

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 7,296	$ 236	$ 508
Costs of goods sold	9,280
Gross margin	(1,984)	236	508
Operating expenses:
Research and development	12,213	10,358	11,508
Selling and supply chain	5,172	2,352	1,241
General and administrative	18,966	13,356	11,580
Management fees	1,338	2,285	1,968
Total operating expenses	37,689	28,351	26,297
Loss from operations	(39,673)	(28,115)	(25,789)
Interest, net	110	264	(1)
Foreign currency transaction (loss)	(49)	(46)	(190)
Loss before income taxes	(39,612)	(27,897)	(25,980)
Income taxes	0	0	0
Net loss	$ (39,612)	$ (27,897)	$ (25,980)
Basic and diluted loss per share	$ (1.21)	$ (0.91)	$ (1.12)
Weighted average shares outstanding - basic and diluted	32,805,684	30,683,421	23,153,661

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Beginning balance at Dec. 31, 2016	$ 13,119	$ 2	$ 41,685		$ (28,568)
Beginning balance, shares at Dec. 31, 2016		19,600,000
Net loss	(25,980)				(25,980)
Issuance of common stock	57,980	$ 1	57,979
Issuance of common stock, shares		8,050,000
Stock-based compensation	12,357		12,357
Stock based compensation, shares		68,780
Ending balance at Dec. 31, 2017	57,476	$ 3	112,021		(54,548)
Ending balance, shares at Dec. 31, 2017		27,718,780
Net loss	(27,897)				(27,897)
Issuance of common stock	57,041		57,041
Issuance of common stock, shares		4,057,500
Stock-based compensation	7,007		7,007
Stock based compensation, shares		888,149
Shares withheld for net share settlement	(230)			$ (230)
Shares withheld for net share settlement, shares		(15,536)
Ending balance at Dec. 31, 2018	93,397	$ 3	176,069	(230)	(82,445)
Ending balance, shares at Dec. 31, 2018		32,648,893
Net loss	(39,612)				(39,612)
Issuance of common stock	344		344
Stock-based compensation	9,175		9,175
Stock based compensation, shares		369,260
Shares withheld for net share settlement	(813)			(813)
Shares withheld for net share settlement, shares		(66,824,000)
Other comprehensive income	17					$ 17
Ending balance at Dec. 31, 2019	$ 62,508	$ 3	$ 185,588	$ (1,043)	$ (122,057)	$ 17
Ending balance, shares at Dec. 31, 2019		32,951,329

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net loss	$ (39,612)	$ (27,897)	$ (25,980)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expenses	1,607	1,081	551
Loss on disposal of land, buildings and equipment		23
Stock-based compensation	9,175	4,385	12,092
Unrealized foreign exchange loss		(12)	(34)
Changes in operating assets and liabilities:
Trade accounts receivable	(1,122)		110
Due to/from related parties	(882)	676	(448)
Inventory	(2,594)
Prepaid expenses and other assets	493	(726)	(537)
Accounts payable	259	(118)	665
Accrued expenses	537	985	86
Accrued compensation and benefits	876	360	613
Other accrued liabilities	(670)	940	97
Other non-current assets	(18)	51
Net cash used by operating activities	(31,951)	(20,252)	(12,785)
Investing activities
Purchases of land, buildings and equipment	(2,969)	(1,847)	(779)
Other		50
Net cash used by investing activities	(2,969)	(1,797)	(779)
Financing activities
Costs incurred related to the issuance of stock		(665)	(3,312)
Proceeds from common stock issuance		57,706	61,292
Repayments of financing lease obligations	(275)
Advances from Cellectis			3,000
Repayment of advances from Cellectis			(3,000)
Proceeds from the exercise of stock options	344	2,622	265
Costs incurred related to shares withheld for net settlement	(813)	(230)
Proceeds from sale and leaseback of land, buildings and equipment	414	1,240	6,957
Net cash (used) provided by financing activities	(330)	60,673	65,202
Net (decrease) increase in cash, cash equivalents and restricted cash	(35,250)	38,624	51,638
Cash, cash equivalents and restricted cash - beginning of period	95,288	56,664	5,026
Cash, cash equivalents and restricted cash - end of period	$ 60,038	$ 95,288	$ 56,664

Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Overview

Calyxt, Inc., formerly known as Cellectis Plant Sciences, Inc. (the “Company” or “Calyxt”), was founded in 2010 and incorporated in Delaware. We are headquartered in Roseville, Minnesota. We are a technology company focused on delivering plant-based solutions that are healthy and sustainable. Prior to our initial public offering (IPO) on July 25, 2017, we were a wholly owned subsidiary of Cellectis S.A. (“Cellectis”). As of December 31, 2019, Cellectis owned 68.9% of our outstanding common stock. Certain prior year amounts have been reclassified to conform to current year presentation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes, including those related to revenue recognition, forward purchase contracts, stock-based compensation and valuation allowances on deferred tax assets. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

We consider all investments purchased with an original maturity of three months or less to be cash equivalents. Restricted cash, which we hold for the benefit of our counterparty on an equipment lease facility, is also invested in cash equivalents.

Accounts Receivable

Accounts receivable are unsecured and are recorded at net realizable value. We make judgments as to our ability to collect outstanding receivables based upon patterns of collectability, historical experience, and our evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. We perform credit evaluations of our customers’ financial condition on an as-needed basis. Payment is generally due fifteen or thirty days from the invoice date depending upon the product, and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off.

Forward Purchase Contracts

We enter into seed and grain production agreements (Forward Purchase Contracts) with seed producers and growers. The seed contracts often require us to pay prices for the seed produced at commodity futures market prices plus a premium. The grower contracts are also linked to commodity futures market prices plus a premium. The grower has the option to fix their price with us throughout the term of the agreement. The grower contracts allow for delivery of grain to us at harvest if so specified when the agreement is executed, otherwise delivery occurs on a date that we elect through August 31 of the following year. In all periods prior to January 1, 2019, we considered Forward Purchase Contracts to be derivatives and recorded the contracts at fair market value with changes in value reflected in earnings as R&D expense.

Effective January 1, 2019, we designated all Forward Purchase Contracts as normal purchases and as a result no longer consider these agreements to be derivatives. As of that date any mark-to-market gains or losses associated with those contracts were fixed and were reflected in upon our purchase of the underlying grain. As of December 31, 2019, we had purchased all the underlying grain and all previously recorded gains and losses had been reflected in inventory.

Inventory

Inventories are recorded at the lower of cost or net realizable value and include all costs of seed production and grain we purchase as well as costs to store, transport and process the grain into finished products. Consideration we receive from growers when they purchase seed is recorded as a reduction of inventory.

We evaluate inventory balances for obsolescence on a regular basis based on the age of the inventory and our sales forecasts. We also determine the net realizable value of our inventory balances using projected selling prices for our products, market prices for the underlying agricultural markets, the age of products our anticipated costs and other factors that take into consideration our limited operating history, and compare those prices to the current weighted average costs of our inventories. If our costs are higher than the projected selling prices a valuation adjustment is recorded.

Prior to our commercialization of high oleic soybean products, all Grain Costs were expensed as R&D.

Fair Value of Financial Instruments

We record financial instruments at fair value with changes in those values reported in our results of operations each period. We determine values using readily available market prices, instruments with similar terms and underlying inputs that are quoted on exchanges, or other valuation techniques if no observable inputs are available.

Land, Buildings and Equipment

Land, buildings and equipment are stated at cost less accumulated depreciation. Assets under capital lease are stated at the lesser of their net present value of future lease payments or fair market value. Depreciation is computed based upon the estimated useful lives of the respective assets. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Repairs and maintenance costs are expensed as incurred. The cost and accumulated depreciation of property and equipment retired, or otherwise disposed of, are removed from the related accounts, and any residual values are charged to expense. Depreciation expense has been calculated using the following estimated useful lives:

Buildings and other improvements		10–20 years
Leasehold improvements		15 years
Office furniture and equipment		7 years
Assets under capital lease		4–20 years
Computer equipment and software		3–5 years
Vehicles		3–6 years

We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset, or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group, further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the carrying value exceeds the fair value of the asset or asset group. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Fair value is measured using a discounted cash flow model or independent appraisals, as appropriate. We have not recognized any impairment losses in these consolidated financial statements.

Revenue Recognition – Product Sales

We recognize sales revenue at the point in time that title transfers to the customer, which is based on shipping terms. Sales include shipping and handling charges if billed to the customer and are reported net of trade promotion and other costs, including estimated allowances for returns, unsalable product and prompt pay discounts. Sales, use, value-added and other excise taxes are not recognized in revenue. Trade promotions are recorded based on estimated participation and performance levels for offered programs at the time of sale. We generally do not allow a right of return.

Revenue Recognition – Out-licensing of Technology

We recognize revenue from license agreements, which may consist of nonrefundable up-front payments, milestone payments, royalties and services. In addition, we may license our technology to third parties.

Nonrefundable up-front payments are deferred and recognized as revenue over the term of the license agreement. If a license agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination.

Milestone payments represent amounts received from our licensees, the receipt of which is dependent upon the achievement of certain scientific, regulatory or commercial milestones. We recognize milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to refund of the payment.

Advertising Costs

We expense advertising costs as incurred.

Research and Development (R&D)

We recognize R&D expenses as incurred. These expenses consist of direct costs for R&D and R&D-related allocations of overhead costs such as facilities and information technology costs. Costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in R&D that have no alternative future use are expensed as incurred. Prior to the commercialization of a product, Grain Costs are expensed as R&D.

Patents

We expense patent costs, including related legal costs, as incurred. Costs to maintain, in-license, and defend patents are recorded as G&A expenses in the statements of operations. Costs to write and support the research for filing patents are recorded as R&D expenses in the statements of operations.

Stock-Based Compensation

We generally measure employee and nonemployee stock-based awards at grant-date fair value and record compensation expense over the vesting period of the award. Prior to our adoption of new accounting rules on January 1, 2019, stock-based awards issued to nonemployees were remeasured until the award vests. We use the Black-Scholes option pricing model to value our stock option awards.

The expected term of stock options is estimated using the average of the vesting tranches and the contractual life of each grant for employee options as we have limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. For options granted to nonemployees, we use the remaining contractual life. For stock price volatility, we use comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free interest rate is based on United States Treasury notes with a term approximating the expected term of the option. We assume no dividend yield because dividends are not expected to be paid.

We generally measure compensation expense for grants of restricted stock units using the value of a share of our stock on the date of grant. Prior to our adoption of new accounting rules on January 1, 2019, compensation expense for grants of stock awards to non-employees were initially measured using the share price on date of grant and remeasured quarterly.

If an award is forfeited prior to vesting the associated reduction in expense is reflected net in stock-based compensation expense in that period. Stock-based compensation expense is recorded in R&D, selling and supply chain, or G&A expenses in our consolidated statements of operations.

Income Taxes

Current income taxes are recorded based on statutory obligations for the current operating period for the jurisdictions in which we have operations.

Deferred taxes are provided on an asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Foreign Currency Transactions

Transactions in foreign currencies are translated at the exchange rates effective on the transaction dates. Assets and liabilities denominated in foreign currencies are translated at the period-end exchange rate. Foreign currency gains and losses are recognized in G&A expenses in the consolidated statements of operations.

Recently Adopted Accounting Pronouncements

Effective January 1, 2019, we adopted new accounting requirements for share-based payment transactions for acquiring goods and services from nonemployees. The adoption did not have an impact on our consolidated financial statements as each of the share-based payment awards granted to nonemployees had a measurement date upon grant, and thus no cumulative adjustment to retained earnings was required.

Effective January 1, 2019, we adopted new accounting requirements for recognition of revenue from contracts with customers. We adopted these requirements using the cumulative effect approach. The adoption did not have an impact on our consolidated financial statements.

In the first quarter of 2019, we adopted new hedge accounting requirements that better aligned our risk management activities and financial reporting. The adoption did not have a material impact on our consolidated financial statements.

Financial Instruments, Fair Value, and Concentrations of Credit Risk

12 Months Ended

Dec. 31, 2019

Text Block [Abstract]

Financial Instruments, Fair Value, and Concentrations of Credit Risk

2. FINANCIAL INSTRUMENTS, FAIR VALUE, AND CONCENTRATIONS OF CREDIT RISK

The carrying values of cash and cash equivalents, restricted cash, due from related parties, accounts payable, due to related parties, and all other current liabilities approximate fair value. The fair value of our financing lease obligations, including the current portion, are $15.7 million as of December 31, 2019, and $15.8 million as of December 31, 2018. The carrying amounts of our financing lease obligations, including the current portion, were $18.6 million as of December 31, 2019 and $18.5 million as of December 31, 2018. The fair value of our financing lease obligations was determined using discounted cash flow analysis based on market rates for similar types of borrowings. Financing lease obligations are a Level 2 liability in the fair value hierarchy.

Fair Value Measurements and Financial Statement Presentation

The fair values of our assets, liabilities, and derivative positions recorded at fair value and their respective levels in the fair value hierarchy as of December 31, 2019 and December 31, 2018, were as follows:

	December 31, 2019								December 31, 2019
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Commodity futures and options	$	62	$	—	$	—	$	62	$	—	$	—	$	—	$	—
Total	$	62	$	—	$	—	$	62	$	—	$	—	$	—	$	—

	December 31, 2018								December 31, 2018
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Forward Purchase Contracts (a)	$	—	$	1	$	—	$	1	$	—	$	248	$	—	$	248
Total	$	—	$	1	$	—	$	1	$	—	$	248	$	—	$	248

(a)	The fair value for forward purchase contracts is estimated based on commodity market future prices.

Commodity Price Risk

We enter Forward Purchase Contracts for grain with settlement values based on commodity futures market prices. These Forward Purchase Contracts allow our counterparty to fix their sale prices to us at various times as defined in the contract. We may enter hedging arrangements to either fix variable exposures or convert fixed prices to floating prices using commodity derivative contracts. As of December 31, 2019, we held commodity contracts with a notional amount of $4.8 million.

We have designated all our commodity derivative contracts as cash flow hedges. As a result, all gains or losses associated with recording commodity derivative contracts at fair value are recorded as a component of accumulated other comprehensive gain (loss) (AOCI). We reclassify amounts from AOCI to cost of goods sold when we sell the underlying products to which those hedges relate. As of December 31, 2019, we expect the entire AOCI balance to be reclassified into earnings within the next six months.

Certain amounts related to our hedging activities are as follows:

	Amount of Gain (Loss)						Amount of Gain (Loss) Reclassified to Earnings
	Recognized in AOCI						Year ended
	December 31,		December 31,		December 31,		December 31,
In thousands	2019		2018		2017		2019			2018		2017
Cash flow hedges:
Commodity contracts	$	17	$	—	$	—	$	(81	)	$	—	$	—
Total	$	17	$	—	$	—	$	(81	)	$	—	$	—

Foreign Exchange Risk

Foreign currency fluctuations affect our foreign currency cash flows related primarily to payments to Cellectis. Our principal foreign currency exposure is to the euro. We do not hedge these exposures, and we do not believe that the current level of foreign currency risk is significant to our operations.

Concentrations of Credit Risk

We invest our cash, cash equivalents and restricted cash in short-term investments and hold deposits at financial institutions that may exceed insured limits. We evaluate the creditworthiness of these institutions in determining the risk associated with these deposits. We have not experienced any losses on these deposits.

Related-Party Transactions

12 Months Ended

Dec. 31, 2019

Related-Party Transactions

3. RELATED-PARTY TRANSACTIONS

We have several agreements that govern our relationship with Cellectis, some of which require us to make payments to Cellectis. Pursuant to our management services agreement with Cellectis, we incurred management fee expenses of $1.3 million in 2019, $2.3 million in 2018 and $2.0 million in 2017.

Cellectis has also guaranteed the lease agreement for our headquarters. Cellectis’ guarantee of our obligations under the lease will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million.

During the year ended December 31, 2018, Cellectis purchased 550,000 shares of common stock in our follow-on offering at the public offering price of $15.00 per share. In addition, in connection with the vesting on June 14, 2018, of restricted stock units for certain of our and Cellectis’ employees and nonemployees, Cellectis purchased 63,175 shares of our common stock at a price of $19.49 per share (the closing price reported on the NASDAQ Global Market on June 14, 2018) directly from such employees and nonemployees in private transactions pursuant to share purchase agreements dated June 13, 2018.

TALEN^® is our primary gene-editing technology, and it is the foundation of our technology platform. TALEN^® technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. We obtained an exclusive license for the TALEN^® technology for commercial use in plants from Cellectis. We also license other technology from Cellectis. We owe Cellectis royalties on any revenue we generate from sales of products less certain amounts as defined in the license agreement, as well as a percentage of any sublicense revenues. We have incurred $328,000 of license and royalty fees for the year ended December 31, 2019 and nominal license and royalty fees for the years ended December 31, 2018 and 2017.

Stockholders' Equity

12 Months Ended

Dec. 31, 2019

Federal Home Loan Banks [Abstract]

Stockholders' Equity

4. STOCKHOLDERS’ EQUITY

Preferred stock of 50.0 million shares, with a $0.0001 par value, is authorized but unissued.

Initial Public Offering

On July 25, 2017, we completed an IPO of our common stock, in which we sold an aggregate of 8,050,000 shares of our common stock at a price of $8.00 per share, including 1,050,000 shares of common stock pursuant to the exercise of the underwriters’ option to purchase additional shares. In the aggregate, we received net proceeds from the IPO and exercise of the overallotment of $58.0 million, after deducting underwriting discounts and commissions of $3.1 million and offering expenses totaling $3.3 million. As part of the IPO, Cellectis purchased 2,500,000 shares of our common stock for a value of $20.0 million, which is included in the net proceeds of $58.0 million. We used $5.7 million of the proceeds from Cellectis to pay a portion of our outstanding obligations to Cellectis.

Follow-on Public Offering

On May 22, 2018, we completed a follow-on offering of our common stock. We sold an aggregate of 4,057,500 shares of common stock at a price of $15.00 per share, including 457,500 shares of common stock pursuant to the exercise of the underwriters’ option to purchase additional shares. In the aggregate, we received net proceeds from the follow-on offering and exercise of the overallotment option of $57.0 million, after deducting underwriting discounts and commissions of $3.2 million and offering expenses totaling$0.7 million. As part of the follow-on offering, Cellectis purchased 550,000 shares of common stock for a value of $8.3 million, the proceeds of which are included in the net proceeds of $57.0 million.

Stock Splits

On June 14, 2017, we effected a stock split of our common stock at a ratio of 100-for-1 and increased the number of shares of common stock authorized for issuance to 30,000,000 by filing a Certificate of Amendment with the Secretary of State of the State of Delaware.

On July 25, 2017, we increased our authorized capital stock to 325,000,000 shares of which 275,000,000 shares are designated common stock, par value $0.0001, and 50,000,000 shares are designated preferred stock, par value $0.0001.

On July 25, 2017, concurrently with the closing of the IPO, we effected a stock split of our common stock at a ratio of 2.45-for-1. As a result of the stock split, each share of issued and outstanding common stock was converted into 2.45 shares of issued and outstanding common stock without changing the par value per share.

Since the par value of the common stock remained at $0.0001 per share subsequent to each stock split, the value of common stock recorded to our balance sheets has been retroactively increased to reflect the par value of the increased number of outstanding shares, with a corresponding decrease to additional paid-in capital. All share and per share data for periods occurring prior to the stock split that are included in the consolidated financial statements and related notes have been retroactively restated to reflect the stock splits.

We repurchased $813,000 of common stock in 2019 and $230,000 in 2018.

Net Loss Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Loss Per Share

5. NET LOSS PER SHARE

Basic and diluted loss per share were calculated using the following:

	Year ended December 31,
In Thousands, Except Share Data and Per Share Amounts	2019			2018			2017
Net loss	$	(39,612	)	$	(27,897	)	$	(25,980	)
Weighted average shares outstanding - basic and diluted		32,805,684			30,683,421			23,153,661
Basic and diluted loss per share	$	(1.21	)	$	(0.91	)	$	(1.12	)

Year ended December 31,

2019

2018

2017

Anti-dilutive stock options, restricted stock units and performance

stock units

5,606,552

4,253,301

5,257,365

All outstanding stock options and restricted stock units are excluded from the calculation since they are anti-dilutive.

We have not used the treasury method in determining the number of anti-dilutive stock options and restricted stock units in the table above.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

6. STOCK-BASED COMPENSATION

We use broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of our shareholders. We have also granted equity-based awards to directors, nonemployees and certain employees of Cellectis.

In December 2014, we adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, we adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, performance shares and other types of equity awards.

As of December 31, 2019, 1,977,594 shares were registered and available for grant under approved registration statements, while 2,544,107 shares were available for grant in the form of stock options, restricted stock, restricted stock units and performance stock units under the 2017 Plan. Stock-based awards now outstanding also include some granted under the 2014 Plan, under which no further awards will be granted.

Stock Options

The estimated fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows:

	2019		2018		2017
Estimated fair values of stock options granted	$	10.18	$	9.09	$	2.42
Assumptions:
Risk-free interest rate	1.7% - 2.5%		2.2% - 3.0%		1.3% - 2.4%
Expected volatility	52.6% - 78.9%		40.9% - 57.2%		27.4% - 45.1%
Expected term (in years)	6.8 - 10		5.6 - 10		1.2 - 10

We estimate the fair value of each option on the grant date or other measurement dates if applicable using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding future stock price volatility, employee exercise behavior and dividend yield. The risk-free interest rate for periods during the expected term of the options is based on the United States Treasury zero-coupon yield curve in effect at the date of grant. We estimate our future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. Our expected term represents the period that options granted are expected to be outstanding determined using the simplified method. We have not paid dividends on our common stock and we do not currently plan to pay any cash dividends in the foreseeable future.

Options may be priced at 100 percent or more of the fair market value on the date of grant and generally vest over six years after the date of grant. Options generally expire within 10 years after the date of grant.

Information on stock option activity follows:

	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share
Balance as of December 31, 2018		1,278,038	$	7.45		3,201,887		$	10.67
Granted						1,590,000			13.80
Exercised						(95,327	)		3.61
Forfeited or expired						(227,696	)		14.68
Other activity						12,495			13.29
Balance as of December 31, 2019		1,789,567	$	8.73		4,481,359		$	11.73

Stock-based compensation expense related to stock option awards was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Stock-based compensation expenses	$	6,035	$	3,609	$	9,291

The aggregate intrinsic value of options exercisable at December 31, 2019 was $3.3 million and the weighted average remaining contractual term was 6.8 years as of that date.

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Net cash proceeds	$	344	$	2,622	$	265
Intrinsic value of options exercised	$	905	$	7,569	$	1,347

As of December 31, 2019, unrecognized compensation expense related to non-vested stock options was $13.1 million. This expense will be recognized over 56 months on average.

Restricted Stock Units

Units settled in stock subject to a restricted period may be granted to key employees under the 2017 Plan. Restricted stock units generally vest and become unrestricted over five years after the date of grant.

Information on restricted stock unit activity follows:

	Number of Restricted Stock Units Outstanding			Weighted- Average Grant Date Fair Value
Unvested balance at December 31, 2018		1,051,414		$	10.15
Granted		100,000			12.48
Vested		(324,043	)		9.69
Cancelled		(13,845	)		12.72
Unvested balance at December 31, 2019		813,526			10.31

The total grant-date fair value of restricted stock unit awards that vested was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Grant-date fair value	$	3,141	$	2,691	$	314

Information on the weighted average grant date fair value of restricted stock units issued was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Weighted average grant date fair value	$	12.48		16.76	$	8.00

Stock-based compensation expense related to restricted stock units was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Stock-based compensation expenses	$	2,910	$	776	$	2,429

We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows.

	Year ended December 31,
In Thousands	2019		2018		2017
Deemed dividends from grants to Cellectis employees	$	1,358	$	2,253	$	3,574

As of December 31, 2019, unrecognized compensation expense related to restricted stock units was $3.0 million. This expense will be recognized over 45 months on average.

Performance Stock Units

In June 2019, we granted 311,667 performance stock units under the 2017 Plan to three executive officers. The performance stock units will vest at 50%, 100% or 120% of the shares under the award at the end of a three-year performance period based upon increases in the value of our common stock from the grant price of $12.48. The performance stock units will be settled in restricted stock upon vesting, with restrictions on transfer lapsing on the second anniversary of the restricted stock issuance date.

The estimated fair values of performance stock units granted and the assumptions used for the Monte Carlo simulation pricing model were as follows:

	Year ended December 31, 2019
Estimated fair values of performance stock units granted	$	7.06
Assumptions:
Risk-free interest rate		1.71	%
Expected volatility		75.0	%
Expected term (in years)	3.0

Stock-based compensation expense related to performance stock unit awards was $225,000 for the year ended December 31, 2019.

As of December 31, 2019, unrecognized compensation expense related to performance stock units was $2.0 million and will be recognized over 54 months.

Cellectis Equity Incentive Plan

Prior to 2018, Cellectis granted stock options to our employees. Compensation costs related to these grants have been recognized in the statements of operations with a corresponding credit to stockholders’ equity, representing the Cellectis’ capital contribution to us. The fair value of each stock option was estimated at the grant date using the Black-Scholes option pricing model.

We recognized stock-based compensation expense related to our Cellectis’ grants of $100,000 in 2018 and $400,000 in 2017. Expenses in 2019 were immaterial and as of December 31, 2019, all expenses related to these awards had been recognized.

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

7. INCOME TAXES

The following table reconciles the United States statutory income tax rate with our effective income tax rate:

	Year ended December 31,
	2019			2018			2017
United States statutory rate		21.0	%		21.0	%		34.0	%
State Tax, net of Federal Benefit		1.0	%		0.7	%		—	%
Stock-based compensation		(1.6	%)		3.6	%		0.6	%
Officers compensation		(1.3	%)		—	%		—	%
Deferred rate change		—	%		0.3	%		(12.9	%)
R&D credit		1.8	%		0.7	%		—	%
Other		0.3	%		0.7	%		—	%
Change in valuation allowance		(21.2	%)		(27.0	%)		(21.7	%)
Effective income tax rate		—	%		—	%		—	%

Deferred assets and liabilities consist of the following:

	December 31,
In Thousands	2019			2018			2017
Net operating losses	$	24,852		$	16,372		$	9,252
Stock-based compensation expenses		3,637			2,747			2,691
Financing lease obligations		4,640			4,009			2,131
Tax credit carry forwards		2,106			922			735
Compensation and employee benefits		97			474			576
Other		307			116			8
Gross deferred tax assets		35,639			24,640			15,393
Less valuation allowance		(30,888	)		(20,329	)		(12,792	)
Net deferred tax assets		4,751			4,311			2,601
Fixed assets		(4,746	)		(4,352	)		(2,600	)
Other		(5	)		41			(1	)
Gross deferred tax liabilities		(4,751	)		(4,311	)		(2,601	)
Net deferred tax asset or liability	$	—		$	—		$	—

We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a valuation allowance against our deferred tax assets described above as current evidence does not suggest we will realize enough taxable income of the appropriate character within the carryforward period to allow us to realize these deferred tax benefits.

We have $141.2 million of tax loss carryforwards. Of this amount, $35.2 million is state operating loss carryforwards and $105.9 million is federal operating loss carryforwards. The federal carryforward periods are as follows: $64.0 million do not expire; zero expire in 2019 and 2020; and $41.9 million expire in 2032 and beyond. The state carryforward period is 20 years.

On December 22, 2017, the TCJA was signed into law. The TCJA results in significant revisions to the United States corporate income tax system, including a reduction in the United States corporate income tax rate, implementation of a territorial system, and a one-time deemed repatriation tax on untaxed foreign earnings. The TCJA also results in a United States federal blended statutory rate of 21 percent for us in 2018. We completed the accounting for the income tax effects of the TCJA as of December 31, 2018.

We are subject to federal income taxes in the United States as well as various state and local jurisdictions. Several years may elapse before an uncertain tax position is audited and finally resolved. While it is often difficult to predict the outcome or the timing of resolution of any uncertain tax position, we do not believe that we need to recognize any liabilities for uncertain tax positions as of December 31, 2019.

The number of years with open tax audits varies depending on the tax jurisdiction. Our major taxing jurisdictions are the United States, both federal and state. Various tax examinations by United States state taxing authorities could be conducted for any open tax year, which vary by jurisdiction, but are generally from 3 to 5 years.

Leases, Other Commitments, and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Leases, Other Commitments, and Contingencies

8. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES

Litigation and Claims

We are not currently a party to any material pending legal proceeding.

Leases

We lease our headquarters facility, office equipment, and other items. Our headquarters lease involved the sale of land and improvements to a third party who then constructed the facility. This lease is considered a financing lease.

Sale-Leaseback of Headquarters and Lab Facility

Our headquarters facility is composed of a 40,000 square-foot office and lab building, with greenhouses and outdoor research plots. We are deemed the owner for accounting purposes. The lease has a term of twenty years, with four options to extend its term for five years each, subject to there being no default under the lease terms beyond any cure period and us occupying the property at the time of extension. In 2017, we received $7.0 million in connection with the sale of the land and uncompleted facility.

The lease commenced in May 2018. Under the lease, we pay an annual base rent of eight percent of the total project cost with scheduled increases in rent of 7.5 percent on the sixth, eleventh and sixteenth anniversaries of the start of the lease commencement as well as on the first day of each renewal term. Currently, we pay an annual base rent of $1.4 million.

We are also responsible for all operating costs and expenses associated with the property. Beginning on the eighteenth month anniversary of the start of the lease, if the landlord decides to sell the property we have a right of first refusal to purchase the property on the same terms offered to any third party.

Concurrent with entering the lease, Cellectis guaranteed all our obligations under the lease agreement. Cellectis’ guarantee of our obligations will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $300 million, as determined in accordance with generally accepted accounting principles. At a point when Cellectis owns 50% or less of our outstanding common stock, we have agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty of our obligations under the lease.

Sale-Leaseback of Equipment

We also have an equipment financing arrangement that is considered a financing lease. This arrangement has a term of four years for each draw. We were required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of December 31, 2019, this restricted cash totaled $1.4 million. We have the option to request the return of excess collateral annually in December. The equipment financing arrangement allows for a six-month renewal option or a repurchase option at the end of the lease term.

Operating Leases

As a lessee, we lease office equipment, storage facilities and vehicles under various operating leases.

Rent expense from all operating leases was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Rent expense from operating leases	$	117	$	200	$	270

Noncancelable future lease commitments are as follows:

In Thousands	Operating Leases		Capital Leases
2020	$	419	$	1,817
2021		59		1,787
2022		13		1,898
2023		—		1,561
2024		—		1,479
After fiscal 2024		—		21,428
Total noncancelable future lease commitments	$	491	$	29,970

Other Commitments

As of December 31, 2019, we have committed to purchase grain from growers and seed from third party producers at dates throughout 2020 and 2021 aggregating $50.9 million based on current commodity futures market prices, other payments to growers and estimated yields per acre. This amount is not recorded in the consolidated financial statements because we have not taken delivery of the grain or seed as of December 31, 2019.

Employee Benefit Plan

12 Months Ended

Dec. 31, 2019

Postemployment Benefits [Abstract]

Employee Benefit Plan

9. EMPLOYEE BENEFIT PLAN

We provide a 401(k) defined contribution plan for all regular full-time employees who have completed three months of service. We match employee contributions up to certain amounts and those matching contributions vest immediately.

	Year ended December 31,
In Thousands	2019		2018		2017
Employee benefit plan expenses	$	228	$	136	$	93

Supplemental Information

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Information

10. SUPPLEMENTAL INFORMATION

Certain balance sheet amounts are as follows:

	December 31,
In Thousands	2019		2018
Inventory:
Raw materials	$	2,211	$	—
Work-in-process		272		—
Finished goods		111		—
Total	$	2,594	$	—

	December 31,
In Thousands	2019			2018
Land, buildings and equipment:
Land under capital lease	$	5,690		$	5,690
Buildings		650			642
Buildings under capital lease		3,812			3,812
Leasehold improvements		130			52
Leasehold improvements under capital lease		10,023			10,023
Office furniture and equipment		4,174			1,789
Office furniture and equipment under capital lease		1,788			1,374
Computer equipment and software		8			2
Construction in progress		550			554
Vehicles		83			0
Total land, buildings and equipment		26,908			23,938
Less accumulated depreciation and amortization		(3,696	)		(2,088	)
Total	$	23,212		$	21,850

Certain statements of operations amounts are as follows:

	Year Ended December 31,
In Thousands	2019		2018		2017
Revenue:
Soybean oil	$	1,685	$	—	$	—
Soybean meal		5,604		—		—
Licensing of technology		7		236		508
Total	$	7,296	$	236	$	508

	Year Ended December 31,
In Thousands	2019		2018		2017
Stock-based compensation expense:
Research and development	$	2,190	$	629	$	6,086
Selling and supply chain		767		408		529
General and administrative		6,218		3,348		5,477
Total	$	9,175	$	4,385	$	12,092

	Year Ended December 31,
In Thousands	2019			2018			2017
Interest, net:
Interest expense	$	(1,490	)	$	(1,257	)	$	(261	)
Interest income		1,600			1,521			260
Total	$	110		$	264		$	(1	)

	Year Ended December 31,
In Thousands	2019		2018		2017
Depreciation and amortization expenses	$	1,607	$	1,081	$	551

Certain statements of cash flows amounts are as follows:

	Year Ended December 31,
In Thousands	2019		2018		2017
Cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	58,610	$	93,794	$	56,664
Restricted cash		388		381		—
Non-current restricted cash		1,040		1,113		—
Total	$	60,038	$	95,288	$	56,664

	Year Ended December 31,
In Thousands	2019		2018		2017
Supplemental investing and financing transactions:
Non-cash additions to land, buildings and equipment	$	414	$	7,994	$	3,130
Offering costs in accounts payable and accrued liabilities	$	—	$	443	$	—
Non-cash addition to financing lease obligations	$	25	$	—	$	—
Interest paid	$	1,472	$	1,086	$	200

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

11. QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2019. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per share data.

	2019												2018
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Revenue	$	157		$	408		$	2,967		$	3,764		$	11		$	196		$	27		$	2
Cost of goods sold	$	(34	)	$	(303	)	$	(3,528	)	$	(5,415	)	$	—		$	—		$	—		$	—
Gross margin	$	123		$	105		$	(561	)	$	(1,651	)	$	11		$	196		$	27		$	2
Operating expenses	$	(7,646	)	$	(9,597	)	$	(10,132	)	$	(10,314	)	$	(4,307	)	$	(7,688	)	$	(7,726	)	$	(8,630	)
Net loss	$	(7,375	)	$	(9,403	)	$	(10,669	)	$	(12,165	)	$	(4,370	)	$	(7,576	)	$	(7,483	)	$	(8,468	)
Net loss per share	$	(0.23	)	$	(0.29	)	$	(0.32	)	$	(0.37	)	$	(0.16	)	$	(0.25	)	$	(0.23	)	$	(0.27	)

Organization and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Use of Estimates

Cash, Cash Equivalents, and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

Accounts Receivable

Forward Purchase Contracts

Inventory

Prior to our commercialization of high oleic soybean products, all Grain Costs were expensed as R&D.

Fair Value of Financial Instruments

Land, Buildings, and Equipment

Land, Buildings and Equipment

Buildings and other improvements		10–20 years
Leasehold improvements		15 years
Office furniture and equipment		7 years
Assets under capital lease		4–20 years
Computer equipment and software		3–5 years
Vehicles		3–6 years

Revenue Recognition

Revenue Recognition – Product Sales

Revenue Recognition – Out-licensing of Technology

Advertising Costs

We expense advertising costs as incurred.

Research and Development (R&D)

Patents

Stock Based Compensation

Stock-Based Compensation

Income Taxes

Current income taxes are recorded based on statutory obligations for the current operating period for the jurisdictions in which we have operations.

Foreign Currency Transactions

Recently Adopted Accounting Pronouncements

Organization and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Estimated Useful Life of Assets Used to Compute Depreciation Using the Straight-line Method

Depreciation expense has been calculated using the following estimated useful lives:

Buildings and other improvements		10–20 years
Leasehold improvements		15 years
Office furniture and equipment		7 years
Assets under capital lease		4–20 years
Computer equipment and software		3–5 years
Vehicles		3–6 years

Financial Instruments, Fair Value, and Concentrations of Credit Risk (Tables)

12 Months Ended

Dec. 31, 2019

Text Block [Abstract]

Summary of Fair Value Measurements and Financial Statement Presentation

	December 31, 2019								December 31, 2019
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Commodity futures and options	$	62	$	—	$	—	$	62	$	—	$	—	$	—	$	—
Total	$	62	$	—	$	—	$	62	$	—	$	—	$	—	$	—

	December 31, 2018								December 31, 2018
	Fair Values of Assets								Fair Values of Liabilities
In Thousands	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Other items reported at fair value:
Forward Purchase Contracts (a)	$	—	$	1	$	—	$	1	$	—	$	248	$	—	$	248
Total	$	—	$	1	$	—	$	1	$	—	$	248	$	—	$	248

(a)	The fair value for forward purchase contracts is estimated based on commodity market future prices.

Summary of Certain Amounts Related to Hedging Activities

Certain amounts related to our hedging activities are as follows:

	Amount of Gain (Loss)						Amount of Gain (Loss) Reclassified to Earnings
	Recognized in AOCI						Year ended
	December 31,		December 31,		December 31,		December 31,
In thousands	2019		2018		2017		2019			2018		2017
Cash flow hedges:
Commodity contracts	$	17	$	—	$	—	$	(81	)	$	—	$	—
Total	$	17	$	—	$	—	$	(81	)	$	—	$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted loss per share were calculated using the following:

	Year ended December 31,
In Thousands, Except Share Data and Per Share Amounts	2019			2018			2017
Net loss	$	(39,612	)	$	(27,897	)	$	(25,980	)
Weighted average shares outstanding - basic and diluted		32,805,684			30,683,421			23,153,661
Basic and diluted loss per share	$	(1.21	)	$	(0.91	)	$	(1.12	)

Year ended December 31,

2019

2018

2017

Anti-dilutive stock options, restricted stock units and performance

stock units

5,606,552

4,253,301

5,257,365

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model

The estimated fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows:

	2019		2018		2017
Estimated fair values of stock options granted	$	10.18	$	9.09	$	2.42
Assumptions:
Risk-free interest rate	1.7% - 2.5%		2.2% - 3.0%		1.3% - 2.4%
Expected volatility	52.6% - 78.9%		40.9% - 57.2%		27.4% - 45.1%
Expected term (in years)	6.8 - 10		5.6 - 10		1.2 - 10

Summary of Stock Option Activity

Information on stock option activity follows:

	Options Exercisable		Weighted- Average Exercise Price Per Share		Options Outstanding			Weighted- Average Exercise Price Per Share
Balance as of December 31, 2018		1,278,038	$	7.45		3,201,887		$	10.67
Granted						1,590,000			13.80
Exercised						(95,327	)		3.61
Forfeited or expired						(227,696	)		14.68
Other activity						12,495			13.29
Balance as of December 31, 2019		1,789,567	$	8.73		4,481,359		$	11.73

Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised

Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Net cash proceeds	$	344	$	2,622	$	265
Intrinsic value of options exercised	$	905	$	7,569	$	1,347

Summary of Activity of Restricted Stock Units

Information on restricted stock unit activity follows:

	Number of Restricted Stock Units Outstanding			Weighted- Average Grant Date Fair Value
Unvested balance at December 31, 2018		1,051,414		$	10.15
Granted		100,000			12.48
Vested		(324,043	)		9.69
Cancelled		(13,845	)		12.72
Unvested balance at December 31, 2019		813,526			10.31

Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested

The total grant-date fair value of restricted stock unit awards that vested was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Grant-date fair value	$	3,141	$	2,691	$	314

Schedule of Weighted Average Grant Date Fair Value of Restricted Stock Units Issued

Information on the weighted average grant date fair value of restricted stock units issued was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Weighted average grant date fair value	$	12.48		16.76	$	8.00

Summary of Stock-Based Compensation Granted As Deemed Dividends

We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows.

	Year ended December 31,
In Thousands	2019		2018		2017
Deemed dividends from grants to Cellectis employees	$	1,358	$	2,253	$	3,574

Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model

The estimated fair values of performance stock units granted and the assumptions used for the Monte Carlo simulation pricing model were as follows:

	Year ended December 31, 2019
Estimated fair values of performance stock units granted	$	7.06
Assumptions:
Risk-free interest rate		1.71	%
Expected volatility		75.0	%
Expected term (in years)	3.0

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to stock option awards was as follows

	Year ended December 31,
In Thousands	2019		2018		2017
Stock-based compensation expenses	$	6,035	$	3,609	$	9,291

Restricted Stock Units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Stock-based Compensation Expense

Stock-based compensation expense related to restricted stock units was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Stock-based compensation expenses	$	2,910	$	776	$	2,429

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Summary of Reconciliation of Statutory IncomeTax Rate

The following table reconciles the United States statutory income tax rate with our effective income tax rate:

	Year ended December 31,
	2019			2018			2017
United States statutory rate		21.0	%		21.0	%		34.0	%
State Tax, net of Federal Benefit		1.0	%		0.7	%		—	%
Stock-based compensation		(1.6	%)		3.6	%		0.6	%
Officers compensation		(1.3	%)		—	%		—	%
Deferred rate change		—	%		0.3	%		(12.9	%)
R&D credit		1.8	%		0.7	%		—	%
Other		0.3	%		0.7	%		—	%
Change in valuation allowance		(21.2	%)		(27.0	%)		(21.7	%)
Effective income tax rate		—	%		—	%		—	%

Schedule of Deferred Tax Assets And Liabilities

Deferred assets and liabilities consist of the following:

	December 31,
In Thousands	2019			2018			2017
Net operating losses	$	24,852		$	16,372		$	9,252
Stock-based compensation expenses		3,637			2,747			2,691
Financing lease obligations		4,640			4,009			2,131
Tax credit carry forwards		2,106			922			735
Compensation and employee benefits		97			474			576
Other		307			116			8
Gross deferred tax assets		35,639			24,640			15,393
Less valuation allowance		(30,888	)		(20,329	)		(12,792	)
Net deferred tax assets		4,751			4,311			2,601
Fixed assets		(4,746	)		(4,352	)		(2,600	)
Other		(5	)		41			(1	)
Gross deferred tax liabilities		(4,751	)		(4,311	)		(2,601	)
Net deferred tax asset or liability	$	—		$	—		$	—

Leases, Other Commitments, and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Lease Cost [Abstract]

Summary of Rent Expense from Operating Leases

Rent expense from all operating leases was as follows:

	Year ended December 31,
In Thousands	2019		2018		2017
Rent expense from operating leases	$	117	$	200	$	270

Schedule of Noncancelable Future Lease Commitments

Noncancelable future lease commitments are as follows:

In Thousands	Operating Leases		Capital Leases
2020	$	419	$	1,817
2021		59		1,787
2022		13		1,898
2023		—		1,561
2024		—		1,479
After fiscal 2024		—		21,428
Total noncancelable future lease commitments	$	491	$	29,970

Employee Benefit Plan (Tables)

12 Months Ended

Dec. 31, 2019

Postemployment Benefits [Abstract]

Summary of Defined Contribution Plan

	Year ended December 31,
In Thousands	2019		2018		2017
Employee benefit plan expenses	$	228	$	136	$	93

Supplemental Information (Tables)

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Certain Balance Sheet Amounts

Certain balance sheet amounts are as follows:

	December 31,
In Thousands	2019		2018
Inventory:
Raw materials	$	2,211	$	—
Work-in-process		272		—
Finished goods		111		—
Total	$	2,594	$	—

	December 31,
In Thousands	2019			2018
Land, buildings and equipment:
Land under capital lease	$	5,690		$	5,690
Buildings		650			642
Buildings under capital lease		3,812			3,812
Leasehold improvements		130			52
Leasehold improvements under capital lease		10,023			10,023
Office furniture and equipment		4,174			1,789
Office furniture and equipment under capital lease		1,788			1,374
Computer equipment and software		8			2
Construction in progress		550			554
Vehicles		83			0
Total land, buildings and equipment		26,908			23,938
Less accumulated depreciation and amortization		(3,696	)		(2,088	)
Total	$	23,212		$	21,850

Schedule of Certain Statements of Operations Amounts

Certain statements of operations amounts are as follows:

	Year Ended December 31,
In Thousands	2019		2018		2017
Revenue:
Soybean oil	$	1,685	$	—	$	—
Soybean meal		5,604		—		—
Licensing of technology		7		236		508
Total	$	7,296	$	236	$	508

	Year Ended December 31,
In Thousands	2019		2018		2017
Stock-based compensation expense:
Research and development	$	2,190	$	629	$	6,086
Selling and supply chain		767		408		529
General and administrative		6,218		3,348		5,477
Total	$	9,175	$	4,385	$	12,092

	Year Ended December 31,
In Thousands	2019			2018			2017
Interest, net:
Interest expense	$	(1,490	)	$	(1,257	)	$	(261	)
Interest income		1,600			1,521			260
Total	$	110		$	264		$	(1	)

	Year Ended December 31,
In Thousands	2019		2018		2017
Depreciation and amortization expenses	$	1,607	$	1,081	$	551

Schedule of Statements of Certain Statements of Cash Flows Amounts

Certain statements of cash flows amounts are as follows:

	Year Ended December 31,
In Thousands	2019		2018		2017
Cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	58,610	$	93,794	$	56,664
Restricted cash		388		381		—
Non-current restricted cash		1,040		1,113		—
Total	$	60,038	$	95,288	$	56,664

	Year Ended December 31,
In Thousands	2019		2018		2017
Supplemental investing and financing transactions:
Non-cash additions to land, buildings and equipment	$	414	$	7,994	$	3,130
Offering costs in accounts payable and accrued liabilities	$	—	$	443	$	—
Non-cash addition to financing lease obligations	$	25	$	—	$	—
Interest paid	$	1,472	$	1,086	$	200

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

	2019												2018
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Revenue	$	157		$	408		$	2,967		$	3,764		$	11		$	196		$	27		$	2
Cost of goods sold	$	(34	)	$	(303	)	$	(3,528	)	$	(5,415	)	$	—		$	—		$	—		$	—
Gross margin	$	123		$	105		$	(561	)	$	(1,651	)	$	11		$	196		$	27		$	2
Operating expenses	$	(7,646	)	$	(9,597	)	$	(10,132	)	$	(10,314	)	$	(4,307	)	$	(7,688	)	$	(7,726	)	$	(8,630	)
Net loss	$	(7,375	)	$	(9,403	)	$	(10,669	)	$	(12,165	)	$	(4,370	)	$	(7,576	)	$	(7,483	)	$	(8,468	)
Net loss per share	$	(0.23	)	$	(0.29	)	$	(0.32	)	$	(0.37	)	$	(0.16	)	$	(0.25	)	$	(0.23	)	$	(0.27	)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 USD ($)
Significant Accounting Policies [Line Items]
Entity Incorporation, State or Country Code	DE
Impairment of long-lived assets	$ 0
Assumed dividend yield	0.00%
Cellectis [Member]
Significant Accounting Policies [Line Items]
Percentage of ownership in outstanding common stock	68.90%

Organization and Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Assets Used to Compute Depreciation Using the Straight-Line Method (Detail)	12 Months Ended
	Dec. 31, 2019
Buildings [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	10 years
Buildings [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	20 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	15 years
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	7 years
Assets under Capital Lease [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	4 years
Assets under Capital Lease [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	20 years
Computer Equipment and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	3 years
Computer Equipment and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	5 years
Vehicles [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	3 years
Vehicles [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets	6 years

Financial Instruments, Fair Value, and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases	$ 15.7	$ 15.8
Financing lease obligations	18.6	$ 18.5
Commodity Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Commodity derivative assets, notional amount	$ 4.8

Financial Instruments, Fair Value, and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) - USD ($)
$ in Thousands

Dec. 31, 2019

Dec. 31, 2018

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

$ 62

$ 1

Fair Values of Liabilities

248

Forward Purchase Contracts [Member]

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

^[1]

Fair Values of Liabilities

^[1]

248

Commodity Futures and Options [Member]

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

Level 1 [Member]

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

Level 1 [Member] | Commodity Futures and Options [Member]

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

$ 62

Level 2 [Member]

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

Fair Values of Liabilities

248

Level 2 [Member] | Forward Purchase Contracts [Member]

Fair Value Concentration Of Risk Financial Statement Captions [Line Items]

Fair Values of Assets

^[1]

Fair Values of Liabilities

^[1]

$ 248

[1]	The fair value for forward purchase contracts is estimated based on commodity market future prices.

Financial Instruments, Fair Value, and Concentrations of Credit Risk - Summary of Certain Amounts Related to Hedging Activities (Detail) - Cash Flow Hedges [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Amount of Gain (Loss) Recognized in AOCI	$ 17
Amount of Gain (Loss) Reclassified to Earnings	(81)
Commodity Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Amount of Gain (Loss) Recognized in AOCI	17
Amount of Gain (Loss) Reclassified to Earnings	$ (81)

Related-Party Transactions - Additional Information (Detail) - USD ($)			12 Months Ended
	May 22, 2018	Jul. 25, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Follow-on Public Offering [Member]
Related Party Transaction [Line Items]
Common stock, issued and sold	4,057,500
Common stock issued price per share	$ 15.00
Cellectis [Member]
Related Party Transaction [Line Items]
Minimum net worth required			$ 300,000,000
Common stock, issued and sold		2,500,000
Cellectis [Member] \| License and Royalty [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party			328,000
Cellectis [Member] \| Restricted Stock Units [Member]
Related Party Transaction [Line Items]
Common stock, issued and sold				63,175
Common stock issued price per share				$ 19.49
Cellectis [Member] \| Follow-on Public Offering [Member]
Related Party Transaction [Line Items]
Common stock, issued and sold	550,000			550,000
Common stock issued price per share				$ 15.00
General and Administrative Expense [Member] \| Cellectis [Member]
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party			$ 1,300,000	$ 2,300,000	$ 2,000,000

Stockholders Equity - Additional Information (Detail)				12 Months Ended
Stockholders Equity - Additional Information (Detail)	May 22, 2018 USD ($) $ / shares shares	Jul. 25, 2017 USD ($) $ / shares shares	Jun. 14, 2017 shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($)
Stockholders Equity [Line Items]
Preferred stock share authorized \| shares				50,000,000
Preferred stock share par value \| $ / shares		$ 0.0001		$ 0.0001
Net proceeds from issuance of common stock upon IPO and exercise of overallotment		$ 58,000,000
Underwriting discounts and commissions		3,100,000
Offering expenses		$ 3,300,000
Net proceeds from issuance of common stock and exercise of overallotment				$ 344,000	$ 57,041,000	$ 57,980,000
Stock split ratio		0.0245	100
Common stock, shares authorized \| shares			30,000,000	275,000,000	275,000,000
Authorised capital stock \| shares		325,000,000
Common stock, shares designated \| shares		275,000,000
Common stock, par value \| $ / shares		$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares designated \| shares		50,000,000
Repurchase of Common Stock				$ 813,000	$ 230,000
Cellectis [Member]
Stockholders Equity [Line Items]
Common stock, issued and sold \| shares		2,500,000
Net proceeds from issuance of common stock and exercise of overallotment		$ 20,000,000
Outstanding obligation paid to parent		$ 5,700,000
IPO [Member]
Stockholders Equity [Line Items]
Common stock, issued and sold \| shares		8,050,000
IPO price per share \| $ / shares		$ 8.00
Underwriters Option to Purchase Additional Shares [Member]
Stockholders Equity [Line Items]
Common stock, issued and sold \| shares	457,500	1,050,000
Follow-on Public Offering [Member]
Stockholders Equity [Line Items]
Common stock, issued and sold \| shares	4,057,500
Underwriting discounts and commissions	$ 3,200,000
Offering expenses	700,000
Net proceeds from issuance of common stock and exercise of overallotment	$ 57,000,000
Common stock issued price per share \| $ / shares	$ 15.00
Follow-on Public Offering [Member] \| Cellectis [Member]
Stockholders Equity [Line Items]
Common stock, issued and sold \| shares	550,000				550,000
Net proceeds from issuance of common stock and exercise of overallotment	$ 8,300,000
Outstanding obligation paid to parent	$ 57,000,000
Common stock issued price per share \| $ / shares					$ 15.00

Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net loss	$ (12,165)	$ (10,669)	$ (9,403)	$ (7,375)	$ (8,468)	$ (7,483)	$ (7,576)	$ (4,370)	$ (39,612)	$ (27,897)	$ (25,980)
Weighted average shares outstanding - basic and diluted									32,805,684	30,683,421	23,153,661
Basic and diluted loss per share									$ (1.21)	$ (0.91)	$ (1.12)
Anti-dilutive stock options, restricted stock units and performance stock units									5,606,552	4,253,301	5,257,365

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Stock-Based Compensation - Additional Information (Detail)	Dec. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	1,977,594
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	2,544,107

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 10,180	$ 9,090	$ 2,420
Risk-free interest rate, minimum	1.70%	2.20%	1.30%
Risk-free interest rate, maximum	2.50%	3.00%	2.40%
Expected volatility, minimum	52.60%	40.90%	27.40%
Expected volatility, maximum	78.90%	57.20%	45.10%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 9 months 18 days	5 years 7 months 6 days	1 year 2 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	10 years	10 years	10 years

Stock-Based Compensation - Stock Options - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	$ 13,100,000
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, percent	100.00%
Stock option expiration period	10 years
Stock option, vesting period	6 years
Weighted average remaining contractual term	6 years 9 months 18 days
Aggregate intrinsic value of options outstanding and exercisable	$ 3,300,000
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends paid on common stock	$ 0
Unrecognized stock-based compensation expense, expected recognition weighted-average period	56 months

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Exercisable, Beginning Balance \| shares	1,278,038
Options Exercisable, Ending Balance \| shares	1,789,567
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 7.45
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	$ 8.73
Options Outstanding, Beginning Balance \| shares	3,201,887
Options Outstanding, Granted \| shares	1,590,000
Options Outstanding, Exercised \| shares	(95,327)
Options Outstanding, Forfeited or expired \| shares	(227,696)
Options Outstanding, Other activity \| shares	12,495
Options Outstanding, Ending Balance \| shares	4,481,359
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 10.67
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	13.80
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	3.61
Weighted-Average Exercise Price Per Share, Forfeited or expired \| $ / shares	14.68
Weighted-Average Exercise Price Per Share, Other activity \| $ / shares	13.29
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	$ 11.73

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 9,175	$ 4,385	$ 12,092
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 6,035	$ 3,609	$ 9,291

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Net cash proceeds	$ 344	$ 2,622	$ 265
Intrinsic value of options exercised	$ 905	$ 7,569	$ 1,347

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 3.0
Unrecognized stock-based compensation expense, expected recognition weighted-average period	45 months
Restricted Stock Units [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance	1,051,414
Number of restricted stock units outstanding, Granted	100,000
Number of restricted stock units outstanding, Vested	(324,043)
Number of restricted stock units outstanding, Cancelled	(13,845)
Number of restricted stock units outstanding, Unvested ending balance	813,526	1,051,414
Weighted-average grant date fair value, Unvested beginning balance	$ 10.15
Weighted-average grant date fair value, Granted	12.48	$ 16.76	$ 8.00
Weighted-average grant date fair value, Vested	9.69
Weighted-average grant date fair value, Cancelled	12.72
Weighted-average grant date fair value, Unvested ending balance	$ 10.31	$ 10.15

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 3,141	$ 2,691	$ 314

Stock-Based Compensation - Schedule of Weighted Average Grant Date Fair Value of Restricted Stock Units Issued (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value, Granted	$ 12.48	$ 16.76	$ 8.00

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 9,175	$ 4,385	$ 12,092
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 2,910	$ 776	$ 2,429

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Nonemployee Restricted Stock Units [Member] \| Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employees	$ 1,358	$ 2,253	$ 3,574

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		1,977,594
Stock-based compensation expenses		$ 9,175,000	$ 4,385,000	$ 12,092,000
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		6 years
Performance stock, shares granted		2,544,107
Performance Stock Units [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Increase in common stock starting price	$ 12.48
Stock-based compensation expenses		$ 225,000
Unrecognized stock-based compensation expense related to performance stock units		$ 2,000,000
Unrecognized stock-based compensation expense, expected recognition weighted-average period		54 months
Performance Stock Units [Member] \| Tranche One [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50.00%
Performance Stock Units [Member] \| Tranche Two [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	100.00%
Performance Stock Units [Member] \| Tranche Three [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	120.00%
Performance Stock Units [Member] \| Three Executive Officers [Member] \| 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	311,667

Stock-Based Compensation - Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model (Detail) - Performance Stock Units [Member]	12 Months Ended
	Dec. 31, 2019 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of performance stock units granted	$ 7.06
Risk-free interest rate	1.71%
Expected volatility	75.00%
Expected term (in years)	3 years

Stock-Based Compensation - Cellectis Equity Incentive Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 9,175,000	$ 4,385,000	$ 12,092,000
Cellectis [Member] \| Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses		$ 100,000	$ 400,000

Income Taxes - Summary of Reconciliation of Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]
United States statutory rate	21.00%	21.00%	34.00%
State Tax, net of Federal Benefit	1.00%	0.70%
Stock-based compensation	(1.60%)	3.60%	0.60%
Officers compensation	(1.30%)
Deferred rate change		0.30%	(12.90%)
R&D credit	1.80%	0.70%
Other	0.30%	0.70%
Change in valuation allowance	(21.20%)	(27.00%)	(21.70%)

Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Components Of Deferred Tax Assets And Liabilities [Abstract]
Net operating losses	$ 24,852	$ 16,372	$ 9,252
Stock-based compensation expenses	3,637	2,747	2,691
Financing lease obligations	4,640	4,009	2,131
Tax credit carry forwards	2,106	922	735
Compensation and employee benefits	97	474	576
Other	307	116	8
Gross deferred tax assets	35,639	24,640	15,393
Less valuation allowance	(30,888)	(20,329)	(12,792)
Net deferred tax assets	4,751	4,311	2,601
Fixed assets	(4,746)	(4,352)	(2,600)
Other	(5)	41	(1)
Gross deferred tax liabilities	$ (4,751)	$ (4,311)	$ (2,601)

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Income tax operating loss carryforwards	$ 141.2
Income tax operating loss carryforwards not expired	64.0
Operating loss carryforwards expiration, 2019	0.0
Operating loss carryforwards Expiration, 2020	0.0
Operating loss carryforwards expiration, 2032 and beyond	$ 41.9
Federal income tax rates	21.00%	21.00%	34.00%
Minimum [Member]
Income Taxes [Line Items]
Income tax examination year under examination	P3Y
Maximum [Member]
Income Taxes [Line Items]
Income tax examination year under examination	P5Y
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards	$ 35.2
State carryforward period	20 years
Federal and state [Member]
Income Taxes [Line Items]
Income tax operating loss carryforwards	$ 105.9

Leases, Other Commitments, and Contingencies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 USD ($) ft² Option	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Other Commitments [Line Items]
Lease term	20 years
Number of lease extension options \| Option	4
Extension term of lease agreement	5 years
Proceeds from sale of land and uncompleted facility			$ 7,000,000
Annual base rent		$ 1,400,000
Percentage of annual base rent		8.00%
Increase in percentage of annual base rent on the sixth, eleventh and sixteenth anniversaries		7.50%
Forward purchase commitment amount	$ 50,900,000
Cellectis [Member]
Other Commitments [Line Items]
Minimum net worth required	$ 300,000,000
Cellectis [Member] \| Maximum [Member]
Other Commitments [Line Items]
Threshold percentage of ownership in outstanding common stock to enact indemnification agreement	50.00%
Corporate Headquarters [Member]
Other Commitments [Line Items]
Office and lab building area \| ft²	40,000
Equipment [Member]
Other Commitments [Line Items]
Lease term	4 years
Extension term of lease agreement	6 months
Restricted cash	$ 1,400,000

Leases, Other Commitments, and Contingencies - Summary of Rent Expense from Operating Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating Leases Rent Expense [Abstract]
Rent expense from operating leases	$ 117	$ 200	$ 270

Leases, Other Commitments, and Contingencies - Schedule of Noncancelable Future Lease Commitments (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Noncancelable Operating Leases [Member]
2020	$ 419
2021	59
2022	13
Total noncancelable future lease commitments	491
Noncancelable Capital Leases [Member]
2020	1,817
2021	1,787
2022	1,898
2023	1,561
2024	1,479
After fiscal 2024	21,428
Total noncancelable future lease commitments	$ 29,970

Employee Benefit Plan - Additional Information (Detail)	12 Months Ended
Employee Benefit Plan - Additional Information (Detail)	Dec. 31, 2019
Compensation Related Costs [Abstract]
Defined contribution plan description	We provide a 401(k) defined contribution plan for all regular full-time employees who have completed three months of service.

Employee Benefit Plan - Summary of Defined Contribution Plan (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Employee benefit plan expenses	$ 228	$ 136	$ 93

Condensed Financial Statements - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Condensed Balance Sheet Statements Captions [Line Items]
Raw materials	$ 2,211
Work-in-process	272
Finished goods	111
Total	2,594
Land, buildings and equipment:
Land, buildings, and equipment	26,908	$ 23,938
Less accumulated depreciation and amortization	(3,696)	(2,088)
Land, buildings, and equipment	23,212	21,850
Land Under Capital Lease [Member]
Land, buildings and equipment:
Land, buildings, and equipment	5,690	5,690
Buildings [Member]
Land, buildings and equipment:
Land, buildings, and equipment	650	642
Buildings Under Capital Lease [Member]
Land, buildings and equipment:
Land, buildings, and equipment	3,812	3,812
Leasehold Improvements [Member]
Land, buildings and equipment:
Land, buildings, and equipment	130	52
Leasehold Improvements Under Capital Lease [Member]
Land, buildings and equipment:
Land, buildings, and equipment	10,023	10,023
Office Furniture and Equipment [Member]
Land, buildings and equipment:
Land, buildings, and equipment	4,174	1,789
Office Furniture and Equipment Under Capital Lease [Member]
Land, buildings and equipment:
Land, buildings, and equipment	1,788	1,374
Computer Equipment and Software [Member]
Land, buildings and equipment:
Land, buildings, and equipment	8	2
Construction in Progress [Member]
Land, buildings and equipment:
Land, buildings, and equipment	550	554
Vehicles [Member]
Land, buildings and equipment:
Land, buildings, and equipment	$ 83	$ 0

Condensed Financial Statements - Summary of Components of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 3,764	$ 2,967	$ 408	$ 157	$ 2	$ 27	$ 196	$ 11	$ 7,296	$ 236	$ 508
Soybean Oil [Member]
Disaggregation of Revenue [Line Items]
Revenue									1,685
Soybean Meal [Member]
Disaggregation of Revenue [Line Items]
Revenue									5,604
Licensing of Technology [Member]
Disaggregation of Revenue [Line Items]
Revenue									$ 7	$ 236	$ 508

Condensed Financial Statements - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 9,175	$ 4,385	$ 12,092
Depreciation and amortization expenses	1,607	1,081	551
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	2,190	629	6,086
Selling and Supply Chain [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	767	408	529
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 6,218	$ 3,348	$ 5,477

Condensed Financial Statements - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Interest expense	$ (1,490)	$ (1,257)	$ (261)
Interest income	1,600	1,521	260
Total	$ 110	$ 264	$ (1)

Condensed Financial Statements - Summary of Statements of Certain Statements of Cash Flows Amounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Cash and cash equivalents	$ 58,610	$ 93,794	$ 56,664
Restricted cash	388	381
Non-current restricted cash	1,040	1,113
Total	60,038	95,288	56,664	$ 5,026
Non-cash additions to land, buildings and equipment	414	7,994	3,130
Offering costs in accounts payable and accrued liabilities		443
Non-cash addition to financing lease obligations	25
Interest paid	$ 1,472	$ 1,086	$ 200

Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Uncategorized [Abstract]
Revenue	$ 3,764	$ 2,967	$ 408	$ 157	$ 2	$ 27	$ 196	$ 11	$ 7,296	$ 236	$ 508
Cost of goods sold	(5,415)	(3,528)	(303)	(34)					(9,280)
Gross margin	(1,651)	(561)	105	123	2	27	196	11	(1,984)	236	508
Operating expenses	(10,314)	(10,132)	(9,597)	(7,646)	(8,630)	(7,726)	(7,688)	(4,307)	(37,689)	(28,351)	(26,297)
Net loss	$ (12,165)	$ (10,669)	$ (9,403)	$ (7,375)	$ (8,468)	$ (7,483)	$ (7,576)	$ (4,370)	$ (39,612)	$ (27,897)	$ (25,980)
Net loss per share	$ (0.37)	$ (0.32)	$ (0.29)	$ (0.23)	$ (0.27)	$ (0.23)	$ (0.25)	$ (0.16)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details